U S Physical Therapy vs GeneDx
USPH and WGS side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How USPH and WGS compare
U S Physical Therapy and GeneDx are about the same size, with market caps of $1.5B and $1.5B.
GeneDx grew revenue faster over the last twelve months (14.6% versus 10.4% for U S Physical Therapy).
U S Physical Therapy keeps more of each dollar of sales as profit, with a net margin of 3.6% compared with −24.1% at GeneDx.
U S Physical Therapy pays a dividend yielding 1.8%; GeneDx does not pay one.
U S Physical Therapy scores higher on the StockData Score (8 against 3 for GeneDx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | USPH | WGS |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $1.5B |
| Share price | $99.60 | $51.87 |
| Change, 1 year | 37.3% | −62.9% |
| Change, 5 years | 9.4% | −78.4% |
| Beta (5Y) | 0.72 | 1.99 |
| Employees | 7,294 | 1,300 |
| StockData Score | ||
| Total score | 8 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 3 (better) | 1 |
| Health score | 2 (better) | 1 |
| Dividend score | 1 (better) | 0 |
| Valuation | ||
| P/S | 1.8× (better) | 3.4× |
| P/B | 3.5× (better) | 6.3× |
| EV/EBITDA | 17.2× | – |
| P/FCF | 21.5× | – |
| FCF yield | 4.6% (better) | −6.5% |
| Fair value | $81.52 | $32.27 |
| Margin of safety | −22.2% (better) | −60.7% |
| Growth | ||
| Revenue growth (TTM) | 10.4% | 14.6% (better) |
| Revenue growth, 5Y average | 13.0% | 19.0% (better) |
| Net income growth (TTM) | −32.5% (better) | −5431% |
| EPS growth (TTM) | – | −6400% |
| EPS growth, 5Y average | −10.6% | – |
| Profitability | ||
| Gross margin | 18.8% | 68.7% (better) |
| Operating margin | 9.1% (better) | −21.6% |
| Net margin | 3.6% (better) | −24.1% |
| FCF margin | 8.2% (better) | −22.0% |
| Return on equity | 6.5% (better) | −41.4% |
| Return on invested capital | 9.1% (better) | −38.4% |
| Financial health | ||
| Debt / equity | 0.57 (better) | 0.60 |
| Net debt / EBITDA | 2.11 | – |
| Current ratio | 1.42 | 4.16 (better) |
| Altman Z-score | 2.84 (better) | 0.16 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 1.8% | – |
| Years of dividend growth | 5 | – |
| Dividend growth, 5Y average | 41.3% | – |
| Shareholder yield | 1.8% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 109% | 107% |
| Held by insiders | 2.6% | – |
| Insider net buying, 12 months | −$397K | $91.2M (better) |
| Short interest, % of float | 7.8% | – |
Go deeper
- USPH stock overview
- USPH income statement
- USPH valuation and score
- WGS stock overview
- WGS income statement
- WGS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.